PR‐957, a selective inhibitor of immunoproteasome subunit low‐MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing T h 17‐cell differentiation and regulating cytokine production

2017 ◽  
Vol 31 (4) ◽  
pp. 1756-1766 ◽  
Author(s):  
Haijie Liu ◽  
Chunxiao Wan ◽  
Yanan Ding ◽  
Ranran Han ◽  
Yating He ◽  
...  
Keyword(s):  
Cell Differentiation ◽  
Cytokine Production ◽  
Selective Inhibitor ◽  
Experimental Autoimmune Neuritis ◽  
Experimental Autoimmune

IL-18 deficiency inhibits both Th1 and Th2 cytokine production but not the clinical symptoms in experimental autoimmune neuritis

2007 ◽  
Vol 183 (1-2) ◽  
pp. 162-167 ◽  
Author(s):  
Rui-Sheng Duan ◽  
Xing-Mei Zhang ◽  
Eilhard Mix ◽  
Hernan Concha Quezada ◽  
Abdu Adem ◽  
...  
Keyword(s):  
Cytokine Production ◽  
Clinical Symptoms ◽  
Experimental Autoimmune Neuritis ◽  
Th2 Cytokine ◽  
Th1 And Th2 ◽  
Experimental Autoimmune

scholarly journals CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Daekwon Bae ◽  
Ji-Young Lee ◽  
Nina Ha ◽  
Jinsol Park ◽  
Jiyeon Baek ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Immune Responses ◽  
Therapeutic Potential ◽  
Autoimmune Encephalitis ◽  
Selective Inhibitor ◽  
Therapeutic Effects ◽  
Treatment Regimens ◽  
Ifn Γ ◽  
Experimental Autoimmune

AbstractDespite advances in therapeutic strategies for multiple sclerosis (MS), the therapy options remain limited with various adverse effects. Here, the therapeutic potential of CKD-506, a novel HDAC6-selective inhibitor, against MS was evaluated in mice with myelin oligodendrocyte glycoprotein35–55 (MOG35–55)-induced experimental autoimmune encephalitis (EAE) under various treatment regimens. CKD-506 exerted prophylactic and therapeutic effects by regulating peripheral immune responses and maintaining blood–brain barrier (BBB) integrity. In MOG35–55-re-stimulated splenocytes, CKD-506 decreased proliferation and downregulated the expression of IFN-γ and IL-17A. CKD-506 downregulated the levels of pro-inflammatory cytokines in the blood of EAE mice. Additionally, CKD-506 decreased the leakage of intravenously administered Evans blue into the spinal cord; CD4+ T cells and CD4−CD11b+CD45+ macrophage/microglia in the spinal cord was also decreased. Moreover, CKD-506 exhibited therapeutic efficacy against MS, even when drug administration was discontinued from day 15 post-EAE induction. Disease exacerbation was not observed when fingolimod was changed to CKD-506 from day 15 post-EAE induction. CKD-506 alleviated depression-like behavior at the pre-symptomatic stage of EAE. In conclusion, CKD-506 exerts therapeutic effects by regulating T cell- and macrophage-mediated peripheral immune responses and strengthening BBB integrity. Our results suggest that CKD-506 is a potential therapeutic agent for MS.

scholarly journals Ginsenoside Rd attenuates mouse experimental autoimmune neuritis by modulating monocyte subsets conversion

2021 ◽  
Vol 138 ◽  
pp. 111489
Author(s):  
Kaixi Ren ◽  
Sanzhong Li ◽  
Jiaqi Ding ◽  
Sijia Zhao ◽  
Shiqian Liang ◽  
...  
Keyword(s):  
Experimental Autoimmune Neuritis ◽  
Monocyte Subsets ◽  
Ginsenoside Rd ◽  
Experimental Autoimmune
Sign in / Sign up

Export Citation Format

Share Document